P/ 310-827-7707 | F/ 310-574-4002 | MAIL@PROSTATEONCOLOGY.COM
BY MARK SCHOLZ, MD Recently, many new anticancer agents have become available for the treatment of prostate cancer—Zytiga, Xtandi, Xofigo, Provenge and Jevtana, but differing opinions about optimal combinations and sequencing …
BY MARK SCHOLZ, MD In Part I and II of this series of articles, the effectiveness treatment initiated at an earlier stage, with either Lupron or Provenge, was compared with the effectiveness of either …
BY MARK SCHOLZ, MD In 2010 the FDA approved Provenge for hormone-refractory prostate cancer. Provenge is a treatment that functions by enhancing the immune system. Some critics have called the effectiveness of …
BY MARK SCHOLZ, MD Dr. Edward Messing tested this premise—that early treatment is superior to delayed treatment—in a study that was reported in The New England Journal of Medicine back in 1999. …